Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05610683
Other study ID # E-FLUX
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 14, 2023
Est. completion date January 31, 2024

Study information

Verified date April 2024
Source Poitiers University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

End-stage renal disease (ESRD) induces an accumulation of uremic toxins responsible for increased morbidity and mortality. These toxins cover a wide range of molecules, classified according to their molecular weight as small-size (< 500 Da), middle-size (500 Da-60 kDa), and protein-bound toxins. Specific complications have been associated with the accumulation of middle-size toxins, including beta2-microglobulin (12 kDa), myoglobin (17 kDa), prolactin (23 kDa), alpha1-microglobulin (33 kDa), alpha1-glycoprotein (44 kDa), kappa (22 kDa) and lambda (45 kDa) free light chains (FLC). Moreover, mediators of oxidative stress such as asymmetric dimethylarginine, malondialdehyde, oxidative-LDL and inflammatory cytokines such as Interleukin-6 (IL)-6, IL1-β, TNF-α have been involved in atherosclerosis, malnutrition, cardiovascular events and mortality. Hemodialysis (HD) remains the main standard modality of renal replacement therapy in ESRD. In the past decade, low-flux hemodialysis was most commonly used, providing effective clearance of small solutes through diffusion, but negligible clearance of middle molecules. This limitation was insufficiently improved by the development of high-flux (HF) dialyzers due to their cut-off pores size values of approximately 15-20 kDa. In fact, most of middle molecules cannot be efficiently removed by HF-HD because of their molecular radii larger than that of membrane pores. Thus, HF dialyzers were used in post dilution on-line hemodiafiltration (OL-HDF) mode with high convection volumes and achieved greatest clearance of middle molecules. However, OL-HDF is generally not available in most HD centers and needs additional hardware technology. Therefore, several super high-flux (SHF) dialyzers integrating higher cut-off size pore value and achieving Beta2-microglobulin clearance > 70 ml/min were developed for HD mode. These SHF dialyzers used in HD (SHF-HD) provides similar middle molecules depuration compared to OL-HDF. The recently developed medium cut-off (MCO) dialyzer (Theranova 500™, Baxter healthcare Corporation Deerfield, USA; surface area 2 m², ultrafiltration coefficient: 59 ml/h/mmHg) differs from conventional HF membranes by higher and controlled porosity resulting in a steep sieving curve with a cut-off value approaching that of albumin. MCO-HD has demonstrated efficient depuration of middle uremic toxins as compared to HF-HD, similar to that of OL-HDF. MCO-HD and SHF-HD are two new large pore size dialyzers currently used nowadays in HD. In addition, the interaction between blood and membrane surface play a key role in generating oxidative stress and inflammation. Antioxidants such as vitamin E work by inhibiting LDL oxidation and by limiting cellular response to oxidized LDL. In HD patients, vitamin E may be integrated as a part of the HD procedure in the form of bioreactive dialysis membranes, in which the blood surface has been modified with alpha-tocopherol. Dialysis with vitamin E-coated membranes has been associated with an improvement in biocompatibility including circulating lipid peroxidation biomarkers and cytokine induction. In small studies, vitamin E coated dialyzers have been associated with reduced red blood count fragility and improvements in erythropoietin resistance index and erythropoietin requirements in HD. VieX (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan), a novel SHF vitamin E-coated (SHVE) dialyzer, which has larger pore size than HF dialyzer, might provide higher middle molecules removal and biocompatibility improvement. The aim of the present study was to compare the efficiency of the SHFVE dialyzer (VieX™) versus the MCO dialyzer (Theranova 500™) on the removal of beta2-microglobulin and other middle molecules in a non-inferiority fashion, and their respective effects on inflammation, oxidative stress and biocompatibility parameters.


Description:

In a previous randomized study, it was found that compared to HF-HD after 3 months, MCO-HD was associated with higher middle molecules removal and significant decrease in beta2-microglobulin, oxidized low-density lipoprotein, kappa and lambda free light chain pre-dialysis levels, without change in other inflammatory and oxidative stress biomarkers. In addition, a modulation of inflammation has been demonstrated with MCO-HD in another randomized trial. After 3 months, MCO-HD was shown to downregulate the expression of the pro-inflammatory IL-6 and tumor necrosis factor (TNF) mRNA in peripheral leucocytes. Moreover, higher removal and decrease in TNF alpha level with concurrent reduced resistance to erythropoiesis stimulating agents (ESA) has been also reported with MCO-HD. VieX (Polysulfone, surface area: 2.1 m², sterilization gamma, ultrafiltration coefficient: 104.3 ml/h/mmHg, Asahi Kasei Medical, Japan), a novel SHF vitamin E-coated dialyzer, which has larger pore size than HF dialyzer, might provide also higher middle molecules removal and more biocompatibility improvement. Preliminary data demonstrate similar reduction ration of beta2-microglobulin, which is the most studied middle molecule, between MCO-HD and Super High Flux Vitamin E (SHFVE)-HD. The aim of the present study was to compare the efficiency of the SHFVE dialyzer versus the MCO dialyzer on the removal of beta2-microglobulin and other middle molecules in a non-inferiority fashion, and their respective effects on inflammation, oxidative stress and biocompatibility parameters.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed informed consent - Age = 18 years - Patients established on HF-HD trice weekly four hour-sessions for at least 3 months Exclusion Criteria: - Malabsorption syndrome, active malignant disease or other critical illnesses and any ongoing condition that may interfere with inflammatory parameters (baseline C-Reactive Protein >40 mg/l) - Pregnant or breast feeding women - Any uncontrolled medical condition, psychiatric disorder or biological abnormality that might interfere with subject's participation or ability to sign an informed consent. - Significant residual kidney function as defined by an urine output > 500 mL.

Study Design


Intervention

Device:
Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months

Locations

Country Name City State
France CHU de Poitiers Poitiers

Sponsors (2)

Lead Sponsor Collaborator
Poitiers University Hospital Hemotech

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Beta2-microglobulin reduction ratio (RR) after 3 months of SHFVE-HD and MCO-HD in a non-inferiority fashion. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05908084 - To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Phase 3
Active, not recruiting NCT05309109 - Effect of Medium Cut-Off Hemodialysis on Protein Energy Wasting: The EMCOPEW Study N/A
Not yet recruiting NCT04086212 - Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine Phase 2
Completed NCT01783626 - Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) N/A
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01219959 - Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients Phase 3
Completed NCT02278341 - Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Phase 3
Completed NCT02593149 - Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap N/A
Withdrawn NCT02274896 - Bayston Multicenter Antimicrobial PD Catheter Safety Study N/A
Completed NCT04912050 - EXtension of Tablo TrEatmeNt Duration Registry
Recruiting NCT02745340 - Substitution of Acetate by Citrate in the Bicarbonate Based Hemodialysis N/A
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT04292184 - Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation Phase 1
Completed NCT02795286 - Automated Setting of Individualized Sodium Technology N/A
Active, not recruiting NCT02808208 - Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure Phase 1/Phase 2
Completed NCT00559767 - Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium N/A
Completed NCT02433210 - A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients N/A
Completed NCT01594424 - A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation Phase 1/Phase 2
Completed NCT03249532 - Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis N/A
Completed NCT02467530 - Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis N/A